All In Biotech

Drug Trial Radar · NCT00106431

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

102

Actual

Start

Jan 1, 2005

Primary completion

Jun 1, 2008

Study completion Dec 1, 2008

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Mar 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia. It assessed the efficacy, safety, and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL). Study patients (pts) received romidepsin in a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although pts who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.

Conditions

  • Cutaneous T-cell Lymphoma

Interventions

  • romidepsin (depsipeptide, FK228)Drug

    Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percent of Patients (Pts) With Objective Disease ResponseTime frame: 6 months

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • UCLA Jonsson Cancer Center

    Los Angeles, California

  • Stanford Comprehensive Cancer Center

    Stanford, California

  • Boston Medical Center

    Boston, Massachusetts

  • University of Pennsylvania Abrahamson Cancer Center

    Philadelphia, Pennsylvania

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Research Site

    Multiple Locations, France

  • Research Site

    Multiple Locations, Germany

  • Research Site

    Multiple Locations, Poland

  • Research Site

    Multiple Locations, Russia

  • Research Site

    Multiple Locations, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.